диссертации / 45

171

212.Smolen J.S., Emery P. Efficacy of Leflunomide Monotherapy in Rheumatoid Arthritis: Towards the Goals of Disease Modifying Antirheumatic Drug Therapy. // J Rheumatol. – 2004. – 31(Suppl 71) – P.13-20.

213.Smolen J.S., Aletana D., Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis. Fact or fiction? // Arthritis Rheum. – 2005. - 52 - P. 2975-83.

214.Smolen J.S., Emery P. (2011) Infliximab: 12 years of experience. // Arthritis Res.Ther. - 13(Suppl. 1) - S2. Abstract.

215.Smolen J.S., Fleischmann R., Emery P. et al. The OPTIMA study of methotrexate and adalimumab: 78-week outcome in early rheumatoid arthritispatients based on achiving o low DAS28 target after 26 weeks. // Ann Rheum Dis. – 2011. -70(Suppl.3) – P.259.(222).

216.Smolen J.S., Han C., van der Heijde et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. // Ann Rheum Dis. -2009. – 68 – P.823-827.

217.Smolen J.S., Kalden J.R., Scott D.L. et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomized, multicenter trial. European Study Group. // Lancet. - 1999. – 353 – P.259-66.

218.Smolen, J. S., van der Heijde, St. Clair W. et al. (2006). Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. // Arthritis Rheum. – 2006. – 54 – P.702-710.

219.Sollinger H.W. Mycophenolate mofetil. Kidney Int Suppl. 1995 Dec;52:S14-7. S.A. Birkeland Mycophenolate mofetil to rescue children with acute renal transplant rejection. // The Lancet. – 1996. - Vol.347 - Issue 9016 – P.1699 – 1700.

171

172

220.Soubrier M., Puechal X., Sibilia J. et al. (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. // Rheumatology (Oxford). – 2009. – 48 – P.1429–1434.

221.Srinivasan Srirangan The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis. // Therapeutic Advances in Musculoskeletal Disease. - 2010 – 2(5) – P.247-256.

222.Keystone E.C., Haraoui B., Guérette B., et all Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. // J. Reumatol. – 2014. - 41(2) – P.235-43.

223.Tak P.P. New Therapeutic Targets in Rheumatoid Arthritis. // Basel. - 2009. – P.59-61.

224.Thomson W., Donn R. Juvenile idiopathic arthritis genetics-what's new? What's next? // Arthritis Res. – 2002. – 4 – P.302–306.

225.Tsakonas E., Fitzgerald A., Fitzcharles M., et al consequences of delay therapy with second-line agents in rheumatoid arthritis: 3-year follow-up of the hydroxychlorouine in early rheumatoid arthritis (HERA) study. // J. Rheumatol.

– 2000. – 27 – P.623-629.

226.T. Takeuchi. Revolutionary Change in Rheumatoid Arthritis Management with Biological Therapy. // The Keio Journal of Medicine. – 2011 – 60(3) - P.75-81.

227.Tubach F., Salmon D., Ravaud P. et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. // Arthritis Rheum. – 2009. - 60(7)

– P.1884-94.

228.Tynjälä P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. // Rheumatology (Oxford). – 2008. - 47(3) – P.339-44.

172

173

229.Uppal S.S., Raghupathy R., Hayat S.J. et al. Disease Activity and Cytokine Production in Mitogen-Stimulated Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis. // Med Princ Pract. – 2010. – 19 – P.33–39.

230.Van Aken J., Lad L.R., Le Cessie S., et al. Radiological outcome after four years of early versus delay treatment strategy in patients with recent onset rheumatoid arthritis. // Ann. Rheum. Dis. – 2004. – 63 – P.274-279.

231.Van de Putte L., Atkins C., Malaise M., et al. Adalimumab monotherapy in the treatment of patients with sever active RA. // Arthr. Rheum. – 2002. - 46(suppl.) - S205.

232.Van de Putte L.B.A., Atkins C., Valaise M. et al. Efficacy and safety of adalimumab in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. // Ann. Rheum.Dis. – 2004. – 63 – P.508-516.

233.Van de Putte L.B.A., van Riel P.L.C.M., der Broeder A. et al. A single-dose, placebo-controlled, phase 1 study of the fully human anti-TNF antibody D2E37 in patients with rheumatoid arthritis. // Arthr Rheum. – 1998. - 41(Suppl. 9) - S57.

234.Van der Kooij S.M., Allaart C.F., de Vries-Bouwstra J.K. et al. Remission induction in Early Rheumatoid Arthritis with initial infliximab and methotrexate therapy: 4-year follow-up data of the disease course after infliximab discontinuation in the BeSt trial // Ann Rheum Dis. – 2007 – 66(Suppl II) – P.192.

235.Vasanthi P., Nalini G., Rajasekhar G. Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review APLAR. // Journal of Rheumatology. – 2007. – 10

– P.270– 274.

236.Vastrt S.J., Kuis W., and Grom A.A. Systemic JIA: New Development in Understending of Pathophysiology and therapy. // Best Prac Res Clin Rheumatol. – 2009 - 23(5) – P.655-64.

237.Vazquez-Cobian L.B., Flynn T., Lehman T.J. Adalimumab therapy for childhood uveitis. // J Pediatr. – 2006. - 149 (4) – P.572-5.

173

174

238.Verstappen S.M.M., Jacobs J.W.G., Bijlsma J.W.J. et al. Five-yaer follow-up of rheumatoid arthritis after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. // Arthritis Reum. – 2003. – 49 – P.1797-1807.

239.Vervoordeldonk M., Tak P.P. Cytocines in rheumatoid arthritis. // Current rheumatology reports. – 2002 - 4(3) – P.208-17.

240.Villarroel M.C., Hidalgo M., Jimeno A. Mycophenolate mofetil: An update. // Drugs Today (Barc). – 2009. - 45(7) – P.521-32.

241.Visvanathan S., Marini J.C., Smolen J.S., et al. Changes in Biomarkers of Inflammation and Bone Turnover and Associations with Clinical Efficacy Following Infliximab plus Methotrexate Therapy in Patients with Early Rheumatoid Arthritis. // J Rheumatol. – 2007. – 34 – P.1465-1474.

242.Visvanathan S., Wagner C., Marini J.C. et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. // Pediatric Rheumatology. – 2010. – 8 –P.24.

243.Wallis R.S. Mycobacterial Disease Attributable to Tumor Necrosis Factor–α Blockers. // Clinical Infectious Diseases. – 2008. – 47(12) – P.1603-1605.

244.Wedderburn L.R., Robinson N., Patel A. et al. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. // Arthritis Rheum. – 2000. – 43 – P.765–774.

245.Wedderburn L.R., Woo P. Juvenile chronic arthritis. // Lancet. - 1998. - 351. - P. 969-973.

246.Weinblatt M., Keystone T., Frust D., et al. Long term efficacy and safety of adalimumab plus methotrxate in patient with RA: ARMADA 4-years study. // Ann. Rheum. Dis. – 2006. – 65 – P.753-759.

247.Weinblatt M., Keystone T., Frust D., et al. The ARMADA trial: efficacy and safety of adalimumab in patient with active RA at 24 months. // Ann. Rheum. Dis. – 2003. - 62(supple.I) – P.98.

174

175

248.Wiegering V., Girschick H. J. and Morbach H. B-Cell Pathology in Juvenile Idiopathic Arthritis. // Arthritis. - 2010 - Article ID 759868 – P.1-6.

249.Winthrop K.L., Chille T. Preventing and treating biologic-associated opportunistic infections Nat. // Rev. Rheumatol. – 2009. – 5 – P.405–410.

250.Winthrop K.L. et al. Risk and Prevention of Tuberculosis and Other Serious Opportunistic Infections Associated with the Inhibition of Tumor Necrosis Factor. // Nat Clin Pract Rheumatol. – 2006. - 2(11) – P.602-610.

251.Yamanaka H., Tanaka Y., Sekiguchi N., et al : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). // Mod Rheumatol. - 2007. – 17 – P.28–32.

252.Yen J.H., Moore B.E., Nakajima T. et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis // J. Exp. Med. – 2001. – 193. – P. 1159-1167.

253.Youn-Soo Hahn, Joong-Gon Kim Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. // Korean J Pediatr. – 2010. - 53(11) – P.921–930.

254.Zang Z.X., Bridges S.L. Pathogenesis of rheumatoid arthritis – Role of B lymphocytes // Rheum. Dis. Clin. N. Am. – 2001. – 27. – P. 335-353.

255.Zannin M.E., Zulian F. New Developments in the Management of Juvenile Idiopathic Arthritis-related Uveitis. // Future Rheumatol. – 2008. - 3(6). – Р.587-59.

175